BRAF antibody (N-Term)

Catalog No. ABIN7862392

The Mouse Monoclonal anti-BRAF antibody (Clone V600E-1322) (ABIN7862392) specifically detects BRAF in ELISA. The antibody is reactive with Human samples.

Quick Overview for BRAF antibody (N-Term) (ABIN7862392)

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This BRAF antibody is un-conjugated

Application: ELISA

Clone: V600E-1322

Product Details anti-BRAF Antibody

Binding Specificity: AA 596-606, N-Term

Purpose: BRAF (V600E Mutant Specific) (Prognostic Marker) Antibody

Specificity: The 79oΩBRAF 79oΩgene encodes a cytoplasmic serine-threonine kinase, which initiates the activation of the mitogen-activated protein kinase (MAPK) signalling pathway. The oncogenic mutations in the kinase region of BRAF gene result in constitutive activation of the MAPK signalling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of all activating BRAF mutations leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. The 79oΩBRAF 79oΩV600E mutation is an important predictive and prognostic biomarker. The BRAF V600E mutation is detected in approximately 8 % of all solid tumours, including 45 % of papillary thyroid carcinomas, 40-60 % of melanomas, 5-15 % of colorectal adenocarcinomas, 35 % of serous low grade and borderline ovarian carcinomas, 1-3 % of non-small cell lung cancers, and 5-7 % of cholangiocarcinomas. 79oΩFurthermore, the BRAF V600E mutation is found in 100 % of hairy cell leukaemia, 79oΩ54 % Erdheim-Chester disease, 38 % of Langerhans cell histocytoses 79oΩand 60 % of pleomorphic xanthoastrocytomas. 79oΩ

Purification: 200ug/ml of Ab purified from rabbit anti-serum by Protein A.

Immunogen: An eleven amino acid residue long synthetic peptide (aa596-606), corresponding to Cys-GLAT(E)KSRWSG from human BRAF protein. It was conjugated to KLH at the N-terminus.

Isotype: IgG, kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Buffer: Prepared in 10  mM PBS

Preservative: Azide free

Storage: -20 °C,-80 °C

Storage Comment: Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C.Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Target Details for BRAF

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Alternative Name: BRAF

Background:

FLJ95109, 94 kDa B raf protein, B Raf proto oncogene, serine/threonine kinase, B RAF1, B-Raf proto-oncogene serine/threonine-protein kinase (p94), BRAF 1, BRAF, BRAF1, cRmil, MGC126806, MGC138284, Murine sarcoma viral (v-raf) oncogene homolog B1, NS7, oncogene BRAF1, p94, Proto-oncogene B-Raf, Proto-oncogene c-Rmil, RAFB1, RMIL, Serine/threonine-protein kinase B-raf, v-Raf murine sarcoma viral oncogene homolog B1

A431|Jurkat or HeLa cells. Human melanoma or colon carcinoma.

Molecular Weight: 35kDa (predicted)

Gene ID: 673, 550061

UniProt: P15056

Pathways: MAPK Signaling, RTK Signaling, Neurotrophin Signaling Pathway, Ribonucleoprotein Complex Subunit Organization, Hepatitis C, Autophagy